Investors & Media

Relay Therapeutics to Participate in Two Upcoming Investor Conferences

November 7, 2022

Relay Therapeutics Reports Third Quarter 2022 Financial Results and Corporate Highlights

November 3, 2022

Relay Therapeutics to Announce Third Quarter 2022 Financial Results and Corporate Highlights

October 27, 2022

Relay Therapeutics to Participate in Fireside Chat at Bank of America Securities 2022 Precision Oncology Conference

September 26, 2022

Relay Therapeutics Announces Pricing of Public Offering of Common Stock  

September 12, 2022

Relay Therapeutics Announces Proposed Public Offering of Common Stock

September 12, 2022

Foundation Medicine and Relay Therapeutics Collaborate to Develop FoundationOne®CDx as a Companion Diagnostic for Relay’s Investigational FGFR2 Inhibitor, RLY-4008

September 12, 2022

Late Breaking Data Presented at ESMO Congress 2022 Demonstrate Potential of RLY-4008 to Transform Treatment Options for Cholangiocarcinoma Patients with FGFR2-Driven Disease

September 11, 2022

Relay Therapeutics to Present Clinical Data on RLY-4008 at ESMO Congress

August 18, 2022

Relay Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highlights

August 4, 2022

Relay Therapeutics to Announce Second Quarter 2022 Financial Results and Corporate Highlights

July 28, 2022

Relay Therapeutics Discloses Anticipated Registrational Path for RLY-4008 in Cholangiocarcinoma and Growing Breast Cancer Franchise at Virtual Analyst and Investor Event

June 27, 2022

Relay Therapeutics Announces Timing of Virtual Analyst and Investor Event

June 16, 2022

Relay Therapeutics to Participate in Two Upcoming Investor Conferences

May 26, 2022

Relay Therapeutics Reports First Quarter 2022 Financial Results and Corporate Highlights

May 5, 2022

Relay Therapeutics to Participate in Fireside Chat at Bank of America Securities 2022 Healthcare Conference

May 3, 2022

Relay Therapeutics to Announce First Quarter 2022 Financial Results and Corporate Highlights

April 28, 2022

Relay Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights

February 24, 2022

Relay Therapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights

February 17, 2022

Relay Therapeutics to Participate in Two Upcoming Investor Conferences

February 2, 2022

Relay Therapeutics Announces Dosing of First Patient in First-in-Human Trial of RLY-2608 and Initiation of Expansion Cohorts for First-In-Human Trial of RLY-4008

January 4, 2022

Relay Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference

January 3, 2022